RxDoctor Payments Data

David Hardesty, MD

Neurology · Arroyo Grande, CANPI 1942239157

Payments from drug & device makers

$26,823in general payments, 2019–2025

Across 154 payments — averaging $174.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$20K
  • Acorda Therapeutics, Inc$5K
  • AbbVie$420
  • Acadia Pharmaceuticals Inc$224
  • Medtronic$179
  • Abbott$166
  • plus $1K from 18 others

What the payments were for

  • Speaking & faculty fees$23,64188%
  • Food & beverage$2,79610%
  • Education$3861%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,823 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$168,093
Medicare patients
285
Services billed
1,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine39$359,649
RytaryCarbidopa/Levodopa156$297,054
Austedo XrDeutetrabenazine32$280,467
NuplazidPimavanserin Tartrate29$176,335
IngrezzaValbenazine Tosylate20$161,457
InbrijaLevodopa13$39,857
BriviactBrivaracetam17$35,062
Aimovig AutoinjectorErenumab-Aooe34$25,229
Carbidopa-LevodopaCarbidopa/Levodopa340$20,825
KeppraLevetiracetam12$13,873
Nurtec OdtRimegepant Sulfate11$11,549
AmantadineAmantadine Hcl78$6,758
Carbidopa-Levodopa ErCarbidopa/Levodopa114$6,534
Memantine Hcl42$3,926
Gabapentin72$2,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$20,176$640,11671 claims
Amneal Pharmaceuticals LLCRytary$60$297,054156 claims
Acadia Pharmaceuticals IncNuplazid$224$176,33529 claims
Neurocrine Biosciences, Inc.Ingrezza$62$161,45720 claims
Acorda Therapeutics, IncInbrija$4,504$39,85713 claims
UCB, Inc.Briviact$19$35,06217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Arroyo Grande

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →